Showing results (251-260 of 291) with videos related to
Sort By:
Pageof 30
The Journal of Steroid Biochemistry and Molecular Biology|May 22, 2023
Metabolism and pharmacokinetics of vitamin D in patients with cystic fibrosisMackenzie C Bergagnini-Kolev, Simon Hsu, Moira L Aitken, et al.Pulmonary Therapy|November 2, 2022
Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene MutationGregory S Sawicki, Michael W Konstan, Edward F McKone, et al.Vaccine|June 1, 1997
Selection of an adjuvant for vaccination with the malaria antigen, MSA-2D Pye, K L Vandenberg, S L Dyer, et al.Annals of the American Thoracic Society|January 23, 2024
Qualitative Analysis of Perspectives on Lung Transplant among People with Cystic FibrosisTijana Milinic, Mara R Hobler, Lauren E Bartlett, et al.Annals of the American Thoracic Society|November 14, 2023
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary ExacerbationsChristina S Thornton, Lindsay J Caverly, Linda M Kalikin, et al.American Journal of Respiratory and Critical Care Medicine|September 1, 2007
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung healthPatrick A Flume, Brian P O'Sullivan, Karen A Robinson, et al.The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 3, 2017
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbationsDon B Sanders, George M Solomon, Valeria V Beckett, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 10, 2023
Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosisAndrew Hart, Francine Cesar, Leila R Zelnick, et al.Mbio|December 14, 2021
Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis InfectionsSamantha L Durfey, Sudhakar Pipavath, Anna Li, et al.Pageof 30